Invivoscribe Inc., a global leader in precision diagnostics, announced on July 7, 2025, its support for CERO Therapeutics Holdings, Inc.'s Phase 1 clinical trial of CER-1236. Invivoscribe's LabPMM customized its multiparametric flow cytometry (MFC) services and implemented its sensitive MFC AML MRD assay to support the trial.
This collaboration is critical for CERo's drug development program, addressing two key needs: assessing the purity of the manufactured T-cell product by detecting residual AML blasts prior to infusion, and evaluating therapeutic response to CER-1236 during the trial. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML.
Kristen Pierce, Ph.D., CERO's Chief Development Officer, stated that Invivoscribe has played an integral role in the execution of this clinical trial, facilitating advancement into the clinic by helping ensure investigational product purity and now assessing therapeutic response. This collaborative effort was instrumental in advancing CER-1236, which recently received FDA Orphan Drug Designation for AML.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.